Seven Eight Capital, LP Provention Bio, Inc. Transaction History

Seven Eight Capital, LP

  • $1.05 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$6.7 - $24.21 $182,447 - $659,262
27,231 New
27,231 $656,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0
View Full List

About Provention Bio, Inc.

PRVB Quotes by TradingView
  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email